Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI)
Cancer · 2025
DOI: 10.1002/cncr.35801 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer, 2025. Verfasst von Massimo Breccia und 55 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University, Roma, Italy. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Pyrazoles. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Farma S.p.A, Italy.
Abstract (Originalsprache)
The study investigated ruxolitinib dosing patterns and correlations with clinical outcomes in patients with myelofibrosis from the ROMEI study. Timely and optimal ruxolitinib treatment demonstrated maximum patient benefits such as spleen size reduction, symptom relief, and improved overall survival, with manageable safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University, Roma, Italy.
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seragnoli, Bologna, Italy.
- A O Policlinico Umberto I Universita La Sapienza, Roma, Italy.
- A O di Cosenza Pres Osped Ospedale dell Annunziata, Cosenza, Italy.
- A.O. Ospedali Riuniti Villa Sofia-Cervello - P.O. Cervello, Palermo, Italy.
- Department of Scienze Mediche, Chirurgiche e Tecnologie Avanzate "G.F. Ingrassia", University of Catania, Catania, Italy.
ORCID-Profile: Massimo Breccia, Francesca Palandri, Nicola Di Renzo, Elisabetta Abruzzese, Giulia Benevolo, Massimiliano Bonifacio, Elena Maria Elli, Mario Tiribelli, Marina Landoni
Förderung
- Novartis Farma S.p.A, Italy
Zitieren
APA
Breccia, M., Palandri, F., Martelli, M., Mendicino, F., Malato, A., Palumbo, G. A., Sibilla, S., Di Renzo, N., Abruzzese, E., Siragusa, S., Crugnola, M., Selleri, C., Pane, F., Sportoletti, P., Martino, B., Impera, S., Ricco, A., Langella, M., Ditonno, P., …, & Passamonti, F. (2025). Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI). Cancer. https://doi.org/10.1002/cncr.35801
Vancouver
Breccia M, Palandri F, Martelli M, Mendicino F, Malato A, Palumbo GA, et al. Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI). Cancer. 2025. doi:10.1002/cncr.35801
BibTeX
@article{Breccia2025,
author = {Breccia, Massimo and Palandri, Francesca and Martelli, Maurizio and Mendicino, Francesco and Malato, Alessandra and Palumbo, Giuseppe A and Sibilla, Silvia and Di Renzo, Nicola and Abruzzese, Elisabetta and Siragusa, Sergio and Crugnola, Monica and Selleri, Carmine and Pane, Fabrizio and Sportoletti, Paolo and Martino, Bruno and Impera, Stefana and Ricco, Alessandra and Langella, Maria and Ditonno, Paolo and Carli, Giuseppe and Itri, Federico and Liberati, Anna Marina and Urbano, Tiziana and Tafuri, Agostino and Polizzi, Vita and Pastore, Domenico and Morsia, Erika and Benevolo, Giulia and Micucci, Giorgia and Farina, Gabriella and Bonifacio, Massimiliano and Elli, Elena Maria and Gardellini, Angelo and De Stefano, Valerio and Caocci, Giovanni and Falcone, Antonietta Pia and Vallisa, Daniele and Brociner, Marco and Tiribelli, Mario and Binotto, Gianni and Pocali, Barbara and Cavazzini, Francesco and Tomassetti, Simona and Lunghi, Francesca and Di Ianni, Mauro and Allegra, Alessandro and Anaclerio, Barbara and Mazzotta, Serena and Orofino, Nicola and Gherlinzoni, Filippo and Castiglioni, Chiara and Landoni, Marina and Valsecchi, Diletta and Magnoli, Michela and Guglielmelli, Paola and Passamonti, Francesco},
title = {Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI)},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35801}
}
EUVIMED